NewAmsterdam Pharma (NASDAQ:NAMS) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research note published on Wednesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $42.00 price target on the stock.

A number of other equities analysts have also weighed in on NAMS. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank lifted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Finally, Needham & Company LLC cut their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.86.

NewAmsterdam Pharma Stock Up 3.2%

NAMS stock opened at $20.14 on Wednesday. The company has a market cap of $2.26 billion, a P/E ratio of -10.71 and a beta of -0.03. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The business has a fifty day moving average of $17.78 and a 200-day moving average of $20.85.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. As a group, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director James N. Topper acquired 1,135 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the acquisition, the director now directly owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. This trade represents a 0.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 20.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently added to or reduced their stakes in NAMS. Quarry LP purchased a new position in shares of NewAmsterdam Pharma in the first quarter worth $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $50,000. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $80,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock valued at $123,000 after purchasing an additional 3,390 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.